ADTPSMA2

ADTPSMA2_tutkimussuunnitelma.pdf

• ClinicalTrials.gov ID: NCT03876912
• Status: Completed

Prostate cancer (PCa) is currently the most common cancer in men (www.cancerregistry.fi). Most common management options for patients with localized PCa are radical prostatectomy, radiotherapy and active surveillance. If metastatic disease develops after curative treatment or in primary metastatic disease, androgen deprivation therapy (ADT) by surgical castration or administration of LhRh-agonists, GnRh-antagonist and antiandrogens has been traditionally used as a first line approach. However, during the natural history of metastatic prostate cancer, majority of men develop castration resistance (CRPC) i.e. prostate cancer progressing regardless of ongoing ADT. At present, CRPC patients are treated sequentially with chemotherapy i.e. docetaxel or cabazitaxel and new generation androgen pathway modulators namely, new generation antiandrogen entsalumide, or the selective CYP17 antagonist, abiraterone.